A cohort study of patients with advanced, unresectable (stage IIIB) metastatic (stage IV) non-squamous non-small cell lung cancer (NSCLC) or in relapse starting treatment with Avastin® in combination with chemotherapy as first line treatment of metastatic disease FRESH-PEF74115-en Camille BACHOT A cohort study of patients with advanced, unresectable (stage IIIB) metastatic (stage IV) non-squamous non-small cell lung cancer (NSCLC) or in relapse starting treatment with Avastin® in combination with chemotherapy as first line treatment of metastatic disease EOLE FRESH-PEF74115-en 74115 FRESH-PEF74115 NCT01333007 F. HOFFMANN-LA ROCHE AG Epidemiology France Portal (PEF) null ;Medical data center Bevacizumab Oncology Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues Healthcare system determinants: Use of care Healthcare system determinants This observational study will evaluate modality, efficacy and safety of Avastin (bevacizumab) as first-line treatment in combination with chemotherapy in patients with inoperable advanced, metastatic or recurrent non-squamous non-small cell lung cancer in clinical practice 1. To describe characteristics of patients treated with Avastin®: demographic and clinical characteristics, history of the disease, and previous disorders and conditions, 2. To describe methods of use of Avastin® in follow-up: doses and durations of treatment with Avastin® (number of cycles); chemotherapy treatments used in combination with treatment with Avastin®; discontinuation of treatment with Avastin® (temporary and permanent) and reasons; treatment strategies set up after discontinuation of treatment with Avastin®, 3. To describe overall survival of patients treated with Avastin®, 4. To describe the safety profile of treatment with Avastin®: serious and non-serious adverse events and targeted adverse events, 5. To describe quality of life: Spitzer's quality of life questionnaire, 6. To describe therapeutic management of patients with non-squamous cell NSCLC in first-line chemotherapy of metastatic disease not receiving Avastin®: compilation of an anonymous registry over a 3-month period starting with time of scientific set up by the investigator. null France Individuals Patients population Male Female Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Aged, 80 and over (80 years and more) Prospective cohort : - Adult, man or woman patient (age >= 18 years), - With unresectable locally advanced (stage IIIB), metastatic (stage IV) or recurrent non squamous (whenever the histology is not predominantly of squamous cell type) non-small cell lung cancer (NSCLC), and treated in first line setting - Patient starting for the first time a treatment with bevacizumab in first line setting, - Patient having received oral and written information on the study and having no objection to the fact that his (her) personal data will be subjected to data processing. Registry : - Patients with unresectable locally advanced (stage IIIB), metastatic (stage IV) or recurrent non squamous non-small cell lung cancer (NSCLC), and treated in first line setting, - Patients for whom the multidisciplinary committee decided to not initiate a treatment with bevacizumab, - Inclusion in the registry had to be consecutive during the first three months of study participation for each investigator. Clinical data GCP/GVP Health event/morbidity Health event/mortality Other Through organizations (health services or institutions schools businesses etc.) < 500 individuals Converting or copying information into a structured record Interview with the participant (including clinical) Observational Study Observational Study Cohort study 418 Unknown Restricted access Access on specific project only